The International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…
Myeloma UK and the UK Spinal Myeloma Working Group have jointly published a paper on the optimal management of spinal disease in myeloma patients. Published in the British Journal of Haematology, the article provides an overview of the treatment and management options for spinal myeloma disease and highlights the role of defined pathways to enable the…
Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…
Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) has been published in the British Journal of Haematology. The publication represents a major milestone for the CTN by marking the completion of its first trial. MUK one, a Phase II multicentre, open label, randomised trial aimed…
The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…
A Myeloma UK funded study has found that myeloma patients regard the impact of symptoms on activity, emotional status and support factors to be the most important issues relating to their quality of life (QOL), highlighting the need to improve existing QOL assessment tools where the emphasis is on symptom status. The study, led by Dr…